IPCA Labs: High-cost inventory a drag in the near term
Traction in domestic business but uncertainty in export side
Amber Enterprises: Long runway for growth
The contract AC maker aims to grow faster than the industry average
Zydus Lifesciences: Nephrology, biosimilar scope takes focus
Valuation reasonable on the back of traction in branded business
Blue Star maintains margin discipline amid market uncertainty
Despite many challenges, Blue Star (BLSTR) outperformed its peers in terms of sales and margins in Q1FY23. Strong order inflows and improvement in operating margins, despite cost pressure, marks a strong beginning for fiscal 2023
Laurus Labs: Diversification picks up pace
Near-term challenges with respect to supply are easing off
Sun Pharma: Slowdown in speciality clinical trials needs to be watched
For FY23, we continue with the estimates that the top line of Sun Pharma would grow in a high single digit only
Cipla: Watch out for respiratory and Peptide pipelines
Cipla is building its Peptide pipeline with the recently launched Lanreotide injection, which has been well received
Dr Reddy’s: China, India to lead EM opportunity
The biggest focus area for Dr Reddy’s is Emerging Markets (EMs). Including India, EMs make up for 43 percent of its sales. In FY23, the company is targeting 130 launches in EMs, of which 30 would be for India
As Fed reaches 'neutral rate', expect some softening in stance
The Fed continues to be “highly attentive to inflation risks” and determined to take the measures needed to bring down inflation to 2 percent goal
Navin Fluorine: Diversification away from agrochemicals to set it apart
Navin Fluorine is increasingly looking towards fluoro applications in performance materials. Among the new product platforms to watch out for would be those of fluoropyridine
SRF: Capex intensity in free flow
Among the recent announcements, what got our attention is more than 50 percent expansion for the belting fabrics capacity to cater to demand as infrastructure spend revives.
Syngene: Multi-year contract with Zoetis adds to long-term visibility
The risk to watch is the execution in the field biologics and the pending regulatory approvals
Gland Pharma: What do acute supply shortages mean for the business & investors?
In the medium to long term, upside triggers can come from biologics CDMO and China opportunity.
Bhansali Engineering: Normalising margins, limited scope for volume growth cap earnings
The challenges to the auto end-market are showing signs of easing, but BEPL’s limited idle capacity restricts it from capitalising on the situation
What does strength in dollar index mean for Indian equities?
One-month rolling return on the Dollar index is more than two standard deviation level higher from the average value of returns for last 20 years– the level at which it generally doesn’t stay long.
Himadri Speciality: What does the future hold?
In the years before COVID disruptions, HSCL used to command premium operating margins, compared to peers such as PCBL and Rain Industries. However, in the past 10 quarters, this is not the case
KIMS: Can it replicate its healthcare success?
In the next few years, KIMS plans to replicate the success of Andhra and Telangana in the adjacent states of Maharashtra and Karnataka
What does Fed’s dilemma — US recession vs inflation — mean for investors?
Fed would reiterate its hawkish stance in the coming meetings as well. While a 75-basis-point hike is widely expected in the July meet, another 75-bps hike during the September meet cannot be ruled out
Clean Science and Technology: Capacity additions to help gain market share
Clean Science and Technology’s progress in capacity addition and product diversification bode well for the company’s future growth
Sumitomo Chemicals India: Steady margin profile catches attention
The company’s superior execution in recent quarters makes it worthy of tracking. We see huge business opportunities emerging from the parent and group companies; investors can buy the stock on market dips
Gland Pharma: Track this inorganic play for the near term
While in the near term, the equity market looks fragile, Gland Pharma makes a cut for the longer haul. This is because of the rising prevalence of chronic diseases and growth of biologics, wherein injectables have a role in treatment and drug delivery
As the Fed steps up inflation fight, how long will the relief rally sustain?
As per FOMC projections, the Federal Funds rate can reach 3.4 percent by the end of this calendar year. This is significantly higher than the March projection of 1.9 percent and implies about 50 bps rate hike each in the remaining four meetings this year
Laurus Labs: This pharma stock gets a shot in the arm
Relatively better growth visibility and the recent steps towards diversification support our long-term conviction on this scrip.
How hard will Powell push the pedal after the latest US inflation data?
Fed Funds futures are pricing in a 75 bps hike in one of the meetings till September
- BHK Voice | A peek into the new home Rakesh Jhunjhunwala was building in Mumbai Watch more
- The last changes Rakesh Jhunjhunwala made to his stock portfolio in in quarter ended June Watch more
- What's behind the rise & fall in currencies? | 5 factors that affect a currency's value | Explained Watch more
- Digital Ads: How much do Google, Facebook earn from ads? How does it work? Watch more
- This fauji turned financial planner helps soldiers plan their finances Watch more